Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Ironwood Pharmaceuticals (NASDAQ: IRWD - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation. Insider and Institutional Ownership 16.9% of Citius

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) has been assigned a consensus rating of "Hold" from the eight analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating on the company.

Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Connor Clark and Lunn Investment Management Ltd. raised its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 48.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,206,948 shares of the biotechnology company's stock after buying an additional 718,904 shares during the

Acadian Asset Management LLC increased its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 147.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,549,687 shares of the biotechnology company's stock after acquiring an additional 3,904,498 shares during the quarter.

Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.

Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.